TOP PHARM CO.,LIMITED

About Us
Factory Tour
Quality Control
Contact Us
Home ProductsOral Anabolic Steroids

99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment

99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment

  • 99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment
  • 99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment
  • 99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment
  • 99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment
99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment
Product Details:
Place of Origin: China
Brand Name: Top Pharm
Certification: IOS 901
Model Number: 81409-90-7
Payment & Shipping Terms:
Minimum Order Quantity: 10g
Price: Negotiable
Packaging Details: As your requirments
Delivery Time: 3-6 working days
Payment Terms: T/T, Western Union, MoneyGram,bitcoin
Supply Ability: bulk stock
Contact Now
Detailed Product Description
Purity: 99% Appearance: White Loose Lyophilized Powder.
Spec: 10G CAS: 98319-26-7
MF: C23H36N2O2 MW: 372.55
High Light:

Anabolic Steroids Finasteride Powder

,

Male Hair Loss Treatment Finasteride Powder

Finasteride

Product name: Finasteride
Alias: Proscar
CAS No: 98319-26-7
MF: C23H36N2O2
MW: 372.55
Purity: 99.68%
Appearance: Off-white crystalline powder.


 

 

Finasteride

 

From Wikipedia, the free encyclopedia
 
 
 
Jump to navigationJump to search
Finasteride
 
 
Clinical data
Trade names Proscar, Propecia, Finide, others
Other names MK-906; YM-152; L-652,931; 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androst-1-en-3-one; N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
AHFS/Drugs.com Monograph
MedlinePlus a698016
License data
Pregnancy
category
Routes of
administration
By mouth
Drug class 5α-Reductase inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 65%[5]
Protein binding 90%[5]
Metabolism Liver (CYP3A4, ALDH)[5]
Elimination half-life Adults: 5–6 hours[5]
Elderly: >8 hours[5]
Excretion Feces: 57%[5]
Urine: 40%[5]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.149.445 Edit this at Wikidata
Chemical and physical data
Formula C23H36N2O2
Molar mass 372.553 g·mol−1
3D model (JSmol)
(verify)

Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used to treat hair loss and benign prostatic hyperplasia in men. It can also be used to treat excessive hair growth in women and as a part of hormone therapy for transgender women.It is taken by mouth.

Finasteride is a 5α-reductase inhibitor and therefore an antiandrogen. It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.

In addition to DHT, finasteride also inhibits the production of several anticonvulsant neurosteroids including allopregnanolone, androstanediol and THDOC.

Adverse effects from finasteride are rare, however some men experience sexual dysfunction, depression, and breast enlargement.In some men, sexual dysfunction may persist after stopping the medication. It may also hide the early symptoms of certain forms of prostate cancer.

Finasteride was patented in 1984 and approved for medical use in 1992. It is available as a generic medication. In 2019, it was the 86th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

 

Medical uses

Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate[3] and for the treatment of male pattern hair loss (androgenetic alopecia) in men.

Enlarged prostate

Physicians sometimes prescribe finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate.Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow.It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment).[medical citation needed] Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3.[medical citation needed] In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years).[medical citation needed] If the drug is discontinued, any therapeutic benefits are reversed within about 6–8 months.

Scalp hair loss

Finasteride is also used to treat male pattern baldness (androgenic alopecia) in men, a condition that develops in up to 80% of Caucasian men.In the United States, finasteride and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017.Treatment with finasteride slows further hair lossand provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken. Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the crown but can reduce hair loss in all areas of the scalp.Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo. Finasteride is less effective in the treatment of scalp hair loss than dutasteride.

Prostate cancer[edit]

In males over 55 years old finasteride decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival.

A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor.A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this.No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer.

Excessive hair growth

Finasteride has been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.

Transgender hormone therapy

Finasteride is sometimes used in hormone replacement therapy for transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of safety or efficacy is limited. Moreover, caution has been recommended when prescribing finasteride to transgender women, as finasteride may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.

Adverse effects

A 2010 Cochrane review of finasteride for BPH found that, in men with a weighted mean age of 62.4, adverse effects are "rare; nevertheless, men taking finasteride are at increased risk for impotence, erectile dysfunction, decreased libido, and ejaculation disorder, versus placebo."As of 2016 fresh evidence suggested such effects, along with disturbed neurosteroid production, may persist after finasteride use is stopped.

Finasteride is contraindicated in pregnancy. The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

The FDA has added a warning to 5α-reductase inhibitors concerning an increased risk of high-grade prostate cancer, as the treatment of BPH lowers PSA (prostate-specific antigen), which could mask the development of prostate cancer. Although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not increased, there are post-marketing reports of breast cancer in association with its use, though available evidence does not provide clarity as to whether there is a causative relationship between finasteride and these cancers.A 2018 meta-analysis found no higher risk of breast cancer with 5α-reductase inhibitors. Some men develop gynecomastia (breast development or enlargement) following finasteride usage.The risk of gynecomastia with 5α-reductase inhibitors is low at about 1.5%.Depressive symptoms and suicidality have been reported.

 

 

Polypeptide Hormones we supply
Melanotan II CAS 121062-08-6 timulate the body's tanning response
Selank CAS 129954-34-3 help enhance mental sharpness,enhance memory
DSIP CAS 62568-57-4 Delta sleep-inducing peptide, abbreviated DSIP
Gonadotropin CAS 71447-49-9 Mainly used for prostate cancer
Tesamorelin CAS 218949-48-5 used in the treatment of HIV-associated lipodystrophy
Triptorelin CAS 57773-63-4 used as the acetate or pamoate salts
HG 176-191   the fat-reducing effects
Pentadecapeptide BPC 157 CAS 137525-51-0 increasing lean muscular tissue mass, reducing fat
TB500 CAS 77591-33-4 oincrease muscle growth
Oxytocin CAS 50-56-6 used for stimulation of uterus contractions
Sermorelin CAS 86168-78-7 Increases the development of lean body mass
Hexarelin CAS 140703-51-1 the treatment of growth hormone secretion deficiency
Ipamorelin CAS 170851-70-4 a selective growth hormone secretagogue
Melanotan 1 CAS 75921-69-6 endogenous melanocortine peptide
MGF   used by bodybuilders and athletes
PEG-MGF   cause site specific muscle growth
CJC-1295 Without DAC CAS 863288-34-0 increasing binding affinity to the GHRH receptors
CJC-1295 with DAC CAS 863288-34-0 improved physique and sense of well being
PT-141   increase libido effects of both men and women
GHRP-2 CAS 158861-67-7 growth hormone stimulation
GHRP-6 CAS 87616-84-0 Increase in strength,Muscle mass,Body fat loss
Tb-500 CAS 77591-33-4 increases in endurance,strength and muscle growth

 

 

 

 

 

 

99% Purity Finasteride CAS 98319-26-7 White Powder Male Hair Loss Treatment 8

Contact Details
TOP PHARM CO.,LIMITED

Contact Person: Baron

Tel: +8618627186113

Send your inquiry directly to us (0 / 3000)